OBJECTIVE: Sepsis-induced multi-organ failure continues to have a high mortality. The liver is an organ central to the disease pathogenesis. The objective of this study was to identify the liver proteins that change in abundance with sepsis and subsequently identify new drug targets. DESIGN: Proteomic discovery study and drug target validation. For the proteomics study, three biological replicate mice were used per group. SETTING: Research institute laboratory. SUBJECTS: Three-month-old C57BL/6 mice. INTERVENTIONS: We used a mouse model of sepsis based on cecal ligation and puncture, but with fluid and antibiotic resuscitation. Liver proteins that changed in abundance were identified by difference in gel electrophoresis. We compared liver proteins from 6-hr post-cecal ligation and puncture to sham-operated mice ("early proteins") and 24-hr post-cecal ligation and puncture with 6-hr post-cecal ligation and puncture ("late proteins"). Proteins that changed in abundance were identified by tandem mass spectrometry. We then inhibited the receptor for one protein and determined the effect on sepsis-induced organ dysfunction. RESULTS: The liver proteins that changed in abundance after sepsis had a range of functions such as acute phase response, coagulation, endoplasmic reticulum stress, oxidative stress, apoptosis, mitochondrial electron transfer proteins, and nitric oxide metabolism. We found that cyclophilin increased in abundance after cecal ligation and puncture. When the receptor for this protein, CD147, was inhibited, sepsis-induced renal dysfunction was reduced. There was also a significant reduction in serum cytokine production when CD147 was inhibited. CONCLUSION: By applying proteomics to a clinically relevant mouse model of sepsis, we identified a number of novel proteins that changed in abundance. The inhibition of the receptor for one of these proteins, cyclophilin, attenuated sepsis-induced acute renal failure. The application of proteomics to sepsis research can facilitate the discovery of new therapeutic targets. (C) 2007 Lippincott Williams & Wilkins, Inc.
OBJECTIVE:Sepsis-induced multi-organ failure continues to have a high mortality. The liver is an organ central to the disease pathogenesis. The objective of this study was to identify the liver proteins that change in abundance with sepsis and subsequently identify new drug targets. DESIGN: Proteomic discovery study and drug target validation. For the proteomics study, three biological replicate mice were used per group. SETTING: Research institute laboratory. SUBJECTS: Three-month-old C57BL/6 mice. INTERVENTIONS: We used a mouse model of sepsis based on cecal ligation and puncture, but with fluid and antibiotic resuscitation. Liver proteins that changed in abundance were identified by difference in gel electrophoresis. We compared liver proteins from 6-hr post-cecal ligation and puncture to sham-operated mice ("early proteins") and 24-hr post-cecal ligation and puncture with 6-hr post-cecal ligation and puncture ("late proteins"). Proteins that changed in abundance were identified by tandem mass spectrometry. We then inhibited the receptor for one protein and determined the effect on sepsis-induced organ dysfunction. RESULTS: The liver proteins that changed in abundance after sepsis had a range of functions such as acute phase response, coagulation, endoplasmic reticulum stress, oxidative stress, apoptosis, mitochondrial electron transfer proteins, and nitric oxide metabolism. We found that cyclophilin increased in abundance after cecal ligation and puncture. When the receptor for this protein, CD147, was inhibited, sepsis-induced renal dysfunction was reduced. There was also a significant reduction in serum cytokine production when CD147 was inhibited. CONCLUSION: By applying proteomics to a clinically relevant mouse model of sepsis, we identified a number of novel proteins that changed in abundance. The inhibition of the receptor for one of these proteins, cyclophilin, attenuated sepsis-induced acute renal failure. The application of proteomics to sepsis research can facilitate the discovery of new therapeutic targets. (C) 2007 Lippincott Williams & Wilkins, Inc.
Authors: Henar Hevia; Marta Varela-Rey; Fernando J Corrales; Carmen Berasain; María L Martínez-Chantar; M Ujue Latasa; Shelly C Lu; José M Mato; Elena R García-Trevijano; Matías A Avila Journal: Hepatology Date: 2004-04 Impact factor: 17.425
Authors: Cristiane Ritter; Michael E Andrades; Adalisa Reinke; Sérgio Menna-Barreto; José Cláudio F Moreira; Felipe Dal-Pizzol Journal: Crit Care Med Date: 2004-02 Impact factor: 7.598
Authors: Takehiko Miyaji; Xuzhen Hu; Peter S T Yuen; Yasunari Muramatsu; Swarnalatha Iyer; Stephen M Hewitt; Robert A Star Journal: Kidney Int Date: 2003-11 Impact factor: 10.612
Authors: Aleksandra Piechota-Polanczyk; Marcin Włodarczyk; Aleksandra Sobolewska-Włodarczyk; Mateusz Jonakowski; Andrzej Pilarczyk; Krystyna Stec-Michalska; Maria Wiśniewska-Jarosińska; Jakub Fichna Journal: Dig Dis Sci Date: 2017-04-08 Impact factor: 3.199
Authors: Asada Leelahavanichkul; Hideo Yasuda; Kent Doi; Xuzhen Hu; Hua Zhou; Peter S T Yuen; Robert A Star Journal: Am J Physiol Renal Physiol Date: 2008-10-15